Competing interests

RF is a member of the advisory board for Kite/Gilead and Autolus; receives research funding from Novartis and Orca Bio; and provides consultancy and honoraria for Sanofi. AM receives research funding from Novartis and Jannsen. AL provides consultancy, receives Honoria, and is a member of the scientific advisory board for Sanofi. HL provides consultancy and honoraria for BioLineRX. SM is on the Speakers Bureau for BMS. TN is on the advisory committee for Medexus; provides consultancy for ImmunoGen; receives research funding from Novartis; and receives personal fees from Karyopharm outside the submitted work. JP provides consultancy and serves on the advisory board/research support for Syndax, CTI Biopharma, Amgen, Regeneron, Incyte, and Sanofi; and receives research support from Novartis, Takeda, Janssen, Johnson and Johnson, Abbvie, and BMS. NB receives research funding from CRISPR; and provides consultancy for CareDX, ORCA Biosystem, AlloVir, Pfizer, and Anthem Bone Marrow/Stem Cell/Cellular Therapy NTQRC. HE receives research funding from BMS and provides consultancy for Shoreline Biosciences. The remainder of the authors have no conflicts of interest to disclose.

Ethics approval and consent to participate

This study was approved by the Moffitt Cancer Center Scientific Review Committee and the University of South Florida Institutional Review Board under Advarra protocol number Pro000064701. The study followed the guidelines set forth in the Declaration of Helsinki. The authors confirm the accuracy of the reported data, analyses, and adherence to the approved study protocol. Data were obtained from the BRAIN database, for which patients provided informed consent prior to transplant, including consent for inclusion in the database.